← Ticker index
DGX
Ticker
DGX
Congressional Trades
23
by 5 members
Ticker disclosure brief
Congressional disclosure records for DGX
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
SELL · 2026-02-17
Largest range
$15K – $50K
Tommy Tuberville
Longest observed gap
261d
Julia Letlow
Highest 30d vs SPY
15.9%
Ro Khanna
Purchase rows
12
52%
Sale rows
10
43%
Disclosed midpoint
$209K
range estimate
Unique Traders
5
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats13 · 57%
Republicans10 · 43%
Federal awards
all →- 2026-07-10$1KDepartment of JusticeOATS-DTH-QUEST DIAGNOSTICS LABS FY26 B1 QTR 3
- 2026-07-09$6KDepartment of JusticeLAB CORP FY 26 MAY-SEPT PENDING FUNDS AVAILABILITY
- 2026-07-07$13KDepartment of JusticeLAB DIAGNOSTICS FOR ADULTS IN CUSTODY @ FDC MIAMI: FY26 OCTOBER 1, 2025 TO NOVEMBER 12, 2025
- 2026-06-30$1.0MDepartment of Veterans AffairsTASK ORDER FOR REFERENCE LAB TESTING SERVICES VISN 12 MULTI-SITE 7/1/2026 - 9/30/2026
- 2026-06-30$0Department of Veterans AffairsVISN 12 MULTI-SITE REFERENCE LABORATORY TESTING SERVICES EO 14398
- 2026-06-26$675KDepartment of Veterans AffairsURGENT BRIDGE SPECIALIZED GENETIC AND ESOTERIC LAB TESTING VISN 2 DOWNSTATE
- 2026-06-22$0Department of Veterans Affairs6-MONTH BRIDGE FSS-BPA VISN 2 SOUTH SPECIALIZED GENETIC AND ESOTERIC LAB TESTING
- 2026-06-16$5KDepartment of JusticeQUEST FY26 MEDICAL B1 LAB TESTING FOR INMATES BPA 15BNAS26A00000038 V797D 70090 THE NEW PERIOD OF PERFORMANCE IS JANUARY 1 2026 MARCH 31 2026
- 2026-06-16$925Department of JusticeFCI MEMPHIS LABORATORY TESTING SERVICES FOR A SERVICE PERIOD OF FY'26 MAY 1-31. REQUESTING $925.04 TO COVER THE LABORATORY TESTING SERVICES
- 2026-06-11$15KDepartment of JusticeFY26 B5 QUEST LAB TESTING MAY 26 SCHEDULE NUMBER: V797D-70090
Lobbying filings
all →- 2026-04-20$690KQUEST DIAGNOSTICS INCORPORATEDFederal policy related to strengthening the clinical laboratory workforce S. 2355 and H.R. 5582 - Patients Deserve Price Tags Act S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act H.R. 6130 - Alzheimers Screening and Prevention Act of 2025 Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program
- 2026-04-20$80KQUEST DIAGNOSTICS INCORPORATEDPolicies, rules, and regulations related to clinical laboratories and Medicare coverage policies. H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare payments for lab tests. S.2761 - RESULTS Act - Issues related to Medicare payments for lab tests. H.R. 7148 - Consolidated Appropriations Act, 2026 - issues related to clinical lab test reimbursement rates.
- 2026-04-20$60KQUEST DIAGNOSTICSdiagnostics, clinical lab reimbursement issues, savings access to lab service, supply chain physician fee schedule, savings access to lab services federal budget issues
- 2026-04-20$50KQUEST DIAGNOSTICS INCORPORATEDIssues related to patient access and affordability of clinical laboratory testing. Issues related to the FY2026 budget and appropriations process Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R. 5269 - RESULTS Act S. 2761 - RESULTS Act
- 2026-01-20$350KQUEST DIAGNOSTICS INCORPORATEDAppropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation S. 2355 and H.R. 5582 - Patients Deserve Price Tags Act S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 Diagnostics and chronic disease prevention and treatment S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Regulatory changes to Sec. 216 of the Protecting Access to Medicare Act of 2014 (PAMA)
- 2026-01-20$330KQUEST DIAGNOSTICS INCORPORATEDFederal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation Federal price transparency legislation related to clinical laboratories S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 P.L. 118-22/H.R. 6363 - Further Continuing Appropriations and Other Extensions Act, 2024, provisions related to Medicare reimbursement for clinical diagnostics and pathology laboratory services Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing
- 2026-01-20$310KQUEST DIAGNOSTICS INCORPORATEDFederal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation Federal price transparency legislation related to clinical laboratories S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 P.L. 118-22/H.R. 6363 - Further Continuing Appropriations and Other Extensions Act, 2024, provisions related to Medicare reimbursement for clinical diagnostics and pathology laboratory services Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Appropriations related to clinical laboratory workforce, PFAS and cardiovascular
- 2026-01-20$80KQUEST DIAGNOSTICS INCORPORATEDPolicies, rules, and regulations related to clinical laboratories and Medicare coverage policies. H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare payments for lab tests. S.2761 - RESULTS Act - Issues related to Medicare payments for lab tests.
- 2026-01-20$60KQUEST DIAGNOSTICSdiagnostics, clinical lab reimbursement issues, savings access to lab service, supply chain physician fee schedule, savings access to lab services federal budget issues
- 2026-01-20$50KQUEST DIAGNOSTICS INCORPORATEDIssues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R. 5269 - RESULTS Act S. 2761 - RESULTS Act Issues related to patient access and affordability of clinical laboratory testing. Issues related to the FY2026 budget and appropriations process
Loading trade analytics…
All Disclosed Trades
Page 1 · 23 of 23 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2026-02-17 | DRo Khanna | SELL | $1K – $15K | 20d | receipt → |
| 2026-02-17 | DRo Khanna | SELL | $1K – $15K | 20d | receipt → |
| 2026-01-29 | DRo Khanna | BUY | $1K – $15K | 8d | receipt → |
| 2026-01-29 | DRo Khanna | BUY | $1K – $15K | 8d | receipt → |
| 2025-07-24 | RJulia Letlow | SELL | $1K – $15K | 174dApparent delay | receipt → |
| 2025-04-28 | RJulia Letlow | BUY | $1K – $15K | 261dApparent delay | receipt → |
| 2025-04-28 | RJulia Letlow | BUY | $1K – $15K | 260dApparent delay | receipt → |
| 2025-07-24 | RJulia Letlow | SELL | $1K – $15K | 173dApparent delay | receipt → |
| 2025-04-28 | RJulia Letlow | BUY | $1K – $15K | 260dApparent delay | receipt → |
| 2025-07-24 | RJulia Letlow | SELL | $1K – $15K | 173dApparent delay | receipt → |
| 2025-11-03 | DJulie Johnson | SELL | $1K – $15K | 39d | receipt → |
| 2025-11-03 | DJulie Johnson | SELL | $1K – $15K | 38d | receipt → |
| 2025-11-03 | DJulie Johnson | SELL | $1K – $15K | 38d | receipt → |
| 2025-03-10 | RCarol Miller | SELL | $1K – $15K | 32d | receipt → |
| 2025-03-10 | RCarol Miller | SELL | $1K – $15K | 32d | receipt → |
| 2025-01-17 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2025-01-17 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2024-11-12 | DRo Khanna | BUY | $1K – $15K | 23d | receipt → |
| 2024-11-12 | DRo Khanna | BUY | $1K – $15K | 23d | receipt → |
| 2024-11-15 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2024-11-15 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2024-01-03 | RTommy Tuberville | PARTIAL_SELL | $15K – $50K | 43d | receipt → |
| 2021-03-29 | RTommy Tuberville | BUY | $1K – $15K | 882dApparent delay | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.